Skip to main content

Market Overview

Seres Stops Enrollment In Melanoma Study, Deprioritizes Further Development

Share:
  • Seres Therapeutics Inc (NASDAQ: MCRB) and its study partners have voluntarily discontinued further enrollment in the Phase 1 study evaluating SER-401 in metastatic melanoma.
  • The company cited challenges related to the pandemic.
  • The study was assessing the safety and drug activity of SER-401 or fecal microbiota transplant (FMT) in combination with nivolumab.
  • A preliminary analysis of results from 10 subjects indicated that SER-401 was safe and well-tolerated.
  • No patients were enrolled in the FMT portion of the study.
  • Subjects currently enrolled in the study will complete the study protocol. 
  • Price Action: MCRB shares gained 0.73% at $19.2 in premarket trading on the last check Monday.
 

Related Articles (MCRB)

View Comments and Join the Discussion!

Posted-In: melanoma phase 1Biotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com